ive barbed monofilament sutures fit very well with our global monofilament sutures campaign, and we are convinced that it will be a major breakthrough for our organization in these markets," said Mr. Miguel Pablo
, Vice President, Marketing, Sales & Regulatory Affairs for the Closure Technologies Unit in the B. Braun Group. "With this agreement, we proudly strengthen our strategic partnership with Angiotech, a leading company in innovative treatment solutions," added Mr. Pablo.
B. Braun is one of the world's leading health care suppliers with over (euro)4 billion in revenue in 2009 and over 39,000 employees worldwide. Its Aesculap division focuses on products and services for core processes in surgery. Aesculap's product portfolio includes, among other items, surgical instruments for open or minimally invasive approaches, implants (including for orthopedics, neurosurgery and spinal surgery), surgical sutures, sterile containers, storage, motor and navigation systems, and products for cardiology.
Forward Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2010 and beyond, our strategies or future actions, our targets, expectations for our financial c
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line2
. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office3
. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation4
. Angiotech to participate in UBS Global Life Sciences Conference5
. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial6
. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line7
. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook8
. Angiotech to participate in Bank of America 2007 Credit Conference9
. Angiotech to participate in RBC 2007 Healthcare Conference10
. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC11
. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction